blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3019610

EP3019610 - METHODS FOR PERFORMING ANTISENSE OLIGONUCLEOTIDE-MEDIATED EXON SKIPPING IN THE RETINA OF A SUBJECT IN NEED THEREOF [Right-click to bookmark this link]
StatusThe patent has been granted
Status updated on  03.04.2020
Database last updated on 03.10.2024
FormerGrant of patent is intended
Status updated on  12.11.2019
FormerExamination is in progress
Status updated on  02.06.2017
Most recent event   Tooltip17.06.2024New entry: Despatch of communication that the patent will be maintained as amended 
Applicant(s)For all designated states
INSERM (Institut National de la Santé et de la Recherche Médicale)
101, rue de Tolbiac
75013 Paris / FR
For all designated states
Fondation Imagine
24, Boulevard du Montparnasse
75015 Paris / FR
For all designated states
Université de Paris
85 boulevard Saint Germain
75006 Paris / FR
For all designated states
ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
55 boulevard Diderot
75012 Paris 12 / FR
[2024/10]
Former [2020/18]For all designated states
INSERM (Institut National de la Santé et de la Recherche Médicale)
101, rue de Tolbiac
75013 Paris / FR
For all designated states
Fondation Imagine
24, Boulevard du Montparnasse
75015 Paris / FR
For all designated states
Université de Paris
85 boulevard Saint Germain
75006 Paris / FR
For all designated states
Assistance Publique-Hôpitaux de Paris (APHP)
3, avenue Victoria
75004 Paris / FR
Former [2019/50]For all designated states
INSERM (Institut National de la Santé et de la Recherche Médicale)
101, rue de Tolbiac
75013 Paris / FR
For all designated states
Fondation Imagine
24, Boulevard du Montparnasse
75015 Paris / FR
For all designated states
Université Paris Descartes
12, rue de l'Ecole de Médecine
75006 Paris / FR
For all designated states
Assistance Publique-Hôpitaux de Paris (APHP)
3, avenue Victoria
75004 Paris / FR
Former [2016/20]For all designated states
INSERM - Institut National de la Santé et de la Recherche Médicale
101, rue de Tolbiac
75013 Paris / FR
For all designated states
Fondation Imagine
Institut des Maladies Genetiques
156, rue de Vaugirard
75015 Paris / FR
For all designated states
Université Paris Descartes - Paris V
12, Rue de l'Ecole de Médecine
75006 Paris / FR
For all designated states
Assistance Publique-Hôpitaux de Paris (APHP)
3, avenue Victoria
75004 Paris / FR
Inventor(s)01 / ROZET, Jean-Michel
Inserm U1163
Imagine
24 Boulevard du Montparnasse
75015 Paris / FR
02 / PERRAULT, Isabelle
Inserm U1163
Imagine
24 Boulevard du Montparnasse
75015 Paris / FR
03 / GERARD, Xavier
Inserm U1163
Imagine
24 Boulevard du Montparnasse
75015 Paris / FR
04 / KAPLAN, Josseline
Inserm U1163
Imagine
24 Boulevard du Montparnasse
75015 Paris / FR
05 / MUNNICH, Arnold
Inserm U1163
Imagine
24 Boulevard du Montparnasse
75015 Paris / FR
 [2016/20]
Representative(s)Lavoix
2, place d'Estienne d'Orves
75441 Paris Cedex 09 / FR
[2020/19]
Former [2016/20]Collin, Matthieu
Inserm-Transfert
Paris Biopark
7, rue Watt
75013 Paris / FR
Application number, filing date14737236.108.07.2014
[2016/20]
WO2014EP64604
Priority number, dateEP2013030596808.07.2013         Original published format: EP 13305968
[2016/20]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2015004133
Date:15.01.2015
Language:EN
[2015/02]
Type: A1 Application with search report 
No.:EP3019610
Date:18.05.2016
Language:EN
The application published by WIPO in one of the EPO official languages on 15.01.2015 takes the place of the publication of the European patent application.
[2016/20]
Type: B1 Patent specification 
No.:EP3019610
Date:06.05.2020
Language:EN
[2020/19]
Search report(s)International search report - published on:EP15.01.2015
ClassificationIPC:C12N15/113, A61K31/7088
[2016/20]
CPC:
C12N15/111 (EP,US); H04W24/08 (KR); A61P25/00 (EP);
A61P25/28 (EP); A61P27/02 (EP); A61P43/00 (EP);
C12N15/113 (EP,US); H04L1/00 (EP); H04L1/1874 (EP);
H04L43/0882 (EP); H04L47/83 (EP); H04W28/0205 (EP,KR);
H04W28/0231 (EP); H04W28/0278 (EP); H04W72/52 (EP,KR);
H04W72/542 (EP); C12N2310/11 (EP,US); C12N2310/315 (EP,US);
C12N2310/321 (EP,US); C12N2310/3521 (EP,US); C12N2320/33 (EP,US);
H04L1/1841 (EP); H04W24/00 (EP) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2016/20]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:VERFAHREN ZUR DURCHFÜHRUNG VON OLIGONUCLEOTIDVERMITTELTEM ANTISENSE-EXON-SKIPPING IN DER NETZHAUT EINER PERSON, DIE DARAUF ANGEWIESEN IST[2019/42]
English:METHODS FOR PERFORMING ANTISENSE OLIGONUCLEOTIDE-MEDIATED EXON SKIPPING IN THE RETINA OF A SUBJECT IN NEED THEREOF[2016/20]
French:PROCÉDÉS PERMETTANT D'EFFECTUER UN SAUT D'EXON INDUIT PAR DES OLIGONUCLÉOTIDES ANTISENS DANS LA RÉTINE D'UN SUJET EN AYANT BESOIN[2019/42]
Former [2016/20]VERFAHREN ZUR DURCHFÜHRUNG VON OLIGONUKLEOTIDVERMITTELTEM ANTISENSE-EXON-SKIPPING IN DER NETZHAUT EINES DARAUF ANGEWIESENEN SUBJEKTS
Former [2016/20]PROCÉDÉS PERMETTANT D'EFFECTUER DES SAUTS D'EXON MÉDIÉS PAR DES OLIGONUCLÉOTIDES ANTISENS DANS LA RÉTINE D'UN SUJET EN AYANT BESOIN
Entry into regional phase08.01.2016National basic fee paid 
08.01.2016Designation fee(s) paid 
08.01.2016Examination fee paid 
Examination procedure08.01.2016Amendment by applicant (claims and/or description)
08.01.2016Examination requested  [2016/20]
02.06.2017Despatch of a communication from the examining division (Time limit: M06)
11.12.2017Reply to a communication from the examining division
15.01.2018Despatch of a communication from the examining division (Time limit: M06)
06.07.2018Reply to a communication from the examining division
09.11.2018Despatch of a communication from the examining division (Time limit: M04)
05.03.2019Reply to a communication from the examining division
11.04.2019Observations by third parties
14.05.2019Despatch of a communication from the examining division (Time limit: M04)
17.06.2019Reply to a communication from the examining division
13.11.2019Communication of intention to grant the patent
23.03.2020Fee for grant paid
23.03.2020Fee for publishing/printing paid
23.03.2020Receipt of the translation of the claim(s)
Divisional application(s)EP20168215.0  / EP3702461
Opposition(s)Opponent(s)01  05.02.2021   
Hoffmann Eitle Patent- und Rechtsanwälte Partnerschaftsgesellschaft mbB
Arabellastr. 30
81925 München / DE
Opponent's representative
Hoffmann Eitle
Patent- und Rechtsanwälte PartmbB
Arabellastraße 30
81925 München / DE
 [N/P]
Former [2021/11]
Opponent(s)01  05.02.2021   
Hoffman Eitle Patent- und Rechtsanwälte Partnerschaftsgesellschaft mbB
Arabellastr. 30
81925 München / DE
Opponent's representative
Hoffmann Eitle
Patent- und Rechtsanwälte PartmbB
Arabellastraße 30
81925 München / DE
23.02.2021Invitation to proprietor to file observations on the notice of opposition
05.07.2021Reply of patent proprietor to notice(s) of opposition
24.01.2024Legal effect of interlocutory decision in opposition
24.01.2024Date of oral proceedings
13.03.2024Despatch of interlocutory decision in opposition
13.03.2024Despatch of minutes of oral proceedings
18.06.2024Despatch of communication that the patent will be maintained as amended
Fees paidRenewal fee
22.07.2016Renewal fee patent year 03
21.07.2017Renewal fee patent year 04
24.07.2018Renewal fee patent year 05
22.07.2019Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU08.07.2014
AL06.05.2020
CY06.05.2020
CZ06.05.2020
DK06.05.2020
EE06.05.2020
FI06.05.2020
HR06.05.2020
LT06.05.2020
LV06.05.2020
MC06.05.2020
MK06.05.2020
MT06.05.2020
PL06.05.2020
RO06.05.2020
RS06.05.2020
SI06.05.2020
SK06.05.2020
SM06.05.2020
TR06.05.2020
BG06.08.2020
NO06.08.2020
GR07.08.2020
IS06.09.2020
PT07.09.2020
[2022/32]
Former [2022/27]HU08.07.2014
AL06.05.2020
CY06.05.2020
CZ06.05.2020
DK06.05.2020
EE06.05.2020
FI06.05.2020
HR06.05.2020
LT06.05.2020
LV06.05.2020
MC06.05.2020
MT06.05.2020
PL06.05.2020
RO06.05.2020
RS06.05.2020
SI06.05.2020
SK06.05.2020
SM06.05.2020
TR06.05.2020
BG06.08.2020
NO06.08.2020
GR07.08.2020
IS06.09.2020
PT07.09.2020
Former [2021/24]AL06.05.2020
CZ06.05.2020
DK06.05.2020
EE06.05.2020
FI06.05.2020
HR06.05.2020
LT06.05.2020
LV06.05.2020
MC06.05.2020
PL06.05.2020
RO06.05.2020
RS06.05.2020
SI06.05.2020
SK06.05.2020
SM06.05.2020
BG06.08.2020
NO06.08.2020
GR07.08.2020
IS06.09.2020
PT07.09.2020
Former [2021/13]AL06.05.2020
CZ06.05.2020
DK06.05.2020
EE06.05.2020
FI06.05.2020
HR06.05.2020
LT06.05.2020
LV06.05.2020
MC06.05.2020
PL06.05.2020
RO06.05.2020
RS06.05.2020
SK06.05.2020
SM06.05.2020
BG06.08.2020
NO06.08.2020
GR07.08.2020
IS06.09.2020
PT07.09.2020
Former [2021/10]AL06.05.2020
CZ06.05.2020
DK06.05.2020
EE06.05.2020
FI06.05.2020
HR06.05.2020
LT06.05.2020
LV06.05.2020
PL06.05.2020
RO06.05.2020
RS06.05.2020
SK06.05.2020
SM06.05.2020
BG06.08.2020
NO06.08.2020
GR07.08.2020
IS06.09.2020
PT07.09.2020
Former [2021/09]AL06.05.2020
CZ06.05.2020
DK06.05.2020
EE06.05.2020
FI06.05.2020
HR06.05.2020
LT06.05.2020
LV06.05.2020
RO06.05.2020
RS06.05.2020
SM06.05.2020
BG06.08.2020
NO06.08.2020
GR07.08.2020
IS06.09.2020
PT07.09.2020
Former [2021/08]AL06.05.2020
DK06.05.2020
FI06.05.2020
HR06.05.2020
LT06.05.2020
LV06.05.2020
RO06.05.2020
RS06.05.2020
SM06.05.2020
BG06.08.2020
NO06.08.2020
GR07.08.2020
IS06.09.2020
PT07.09.2020
Former [2021/04]AL06.05.2020
FI06.05.2020
HR06.05.2020
LT06.05.2020
LV06.05.2020
RS06.05.2020
BG06.08.2020
NO06.08.2020
GR07.08.2020
IS06.09.2020
PT07.09.2020
Former [2021/01]FI06.05.2020
HR06.05.2020
LT06.05.2020
LV06.05.2020
RS06.05.2020
BG06.08.2020
NO06.08.2020
GR07.08.2020
IS06.09.2020
PT07.09.2020
Former [2020/51]FI06.05.2020
HR06.05.2020
LT06.05.2020
LV06.05.2020
RS06.05.2020
NO06.08.2020
GR07.08.2020
IS06.09.2020
PT07.09.2020
Former [2020/50]FI06.05.2020
HR06.05.2020
LT06.05.2020
LV06.05.2020
NO06.08.2020
GR07.08.2020
IS06.09.2020
PT07.09.2020
Former [2020/48]FI06.05.2020
LT06.05.2020
NO06.08.2020
IS06.09.2020
PT07.09.2020
Former [2020/47]LT06.05.2020
NO06.08.2020
IS06.09.2020
Former [2020/46]IS06.09.2020
Cited inInternational search[X]WO2012168435  (INST NAT SANTE RECH MED [FR], et al) [X] 1-8 * page 9, line 2 - line 5 * * the whole document *;
 [YD]WO2013036105  (STICHTING KATHOLIEKE UNIV [NL], et al) [YD] 1-8 * the whole document *;
 [YD]  - XAVIER GERARD ET AL., "AON-mediated exon skipping restores ciliation in fibroblasts harboring the common Leber congenital amaurosis CEP290 mutation", MOLECULAR THERAPY - NUCLEIC ACIDS, (20120601), vol. 1, no. 6, doi:10.1038/mtna.2012.21, ISSN 2162-2531, page e29, XP055088066 [YD] 1-8 * the whole document *

DOI:   http://dx.doi.org/10.1038/mtna.2012.21
 [Y]  - XAVIER G. et al., "AON-mediated exon skipping restores ciliation in fibroblasts harboring the common Leber congenital amaurosis CEP290 mutation- Supplementary Information", (20120601), URL: http://www.nature.com/mtna/journal/v1/n6/suppinfo/mtna201221s1.html?url=/mtna/journal/v1/n6/full/mtna201221a.html, (20131113), XP002716312 [Y] 1-8

DOI:   http://dx.doi.org/10.1038/mtna.2012.21
 [Y]  - ROB WJ COLLIN ET AL., "Antisense Oligonucleotide (AON)-based Therapy for Leber Congenital Amaurosis Caused by a Frequent Mutation in CEP290", MOLECULAR THERAPY - NUCLEIC ACIDS, (20120301), vol. 1, no. 3, doi:10.1038/mtna.2012.3, page e14, XP055088070 [Y] 1-8 * the whole document *

DOI:   http://dx.doi.org/10.1038/mtna.2012.3
 [Y]  - RAKOCZY PIROSKA E. ET AL., "Targeted delivery of an antisense oligonucleotide in the retina: uptake, distribution, stability, and effect", ANTISENSE AND NUCLEIC ACID DRUG DEVELOPMENT, (1996), vol. 6, no. 3, ISSN 1087-2906, pages 207 - 213, XP002716313 [Y] 1-8 * the whole document *

DOI:   http://dx.doi.org/10.1089/oli.1.1996.6.207
 [Y]  - BOCHOT A. ET AL., "Intravitreal administration of antisense oligonucleotides: Potential of liposomal delivery", PROGRESS IN RETINAL AND EYE RESEARCH, (200003), vol. 19, no. 2, ISSN 1350-9462, pages 131 - 147, XP002716314 [Y] 1-8 * the whole document *

DOI:   http://dx.doi.org/10.1016/S1350-9462(99)00014-2
by applicantWO2012168435
    - KAPLAN, J. OPHTHALMIC GENET., (2008), vol. 29, pages 92 - 8
    - HOLLANDER, AI ET AL., PROG RETIN EYE RES., (2008), vol. 27, pages 391 - 419
    - DEN HOLLANDER, AI ET AL., AM J HUM GENET., (2006), vol. 79, pages 556 - 61
    - PERRAULT, I ET AL., HUM MUTAT., (2007), vol. 28, page 416
    - TURNER, CSH SYMP. QUANT. BIOL., (1987), vol. 1/7, pages 123 - 133
    - FRIER ET AL., PROC. NAT. ACAD. SCI. USA, (1986), vol. 83, pages 9373 - 77
    - TURNER ET AL., J. AM. CHEM. SOC., (1987), vol. 109, pages 3783 - 3785
    - TAKAGI M; YAGI M; ISHIBASHI K; TAKESHIMA Y; SURONO A; MATSUO M; KOIZUMI M, "Design of 2'-O-Me RNA/ENA chimera oligonucleotides to induce exon skipping in dystrophin pre-mRNA", NUCLEIC ACIDS SYMP SER (OXF, (2004), doi:doi:10.1093/nass/48.1.297, pages 297 - 8, XP003031264

DOI:   http://dx.doi.org/10.1093/nass/48.1.297
 US20090212384
otherWO2012168435
    - UEHARA et al., FASEB Journal, (20120920), vol. 27, no. 1, pages 76 - 85
    - ANDRIEU-SOLER et al., Molecular Vision, (20070000), vol. 13, pages 692 - 706
OppositionEP0064604
 EP0305968
 WO2012168435
 WO2013036105
 EP2718437
    - Xavier Gerard, Isabelle Perrault, Sylvain Hanein, Eduardo Silva, Karine Bigot, Sabine Defoort-Delhemmes, Marlèene Rio, Arnold Munnich, Daniel Scherman, Josseline Kaplan, Antoine Kichler, Jean-Michel Rozet, "AON-mediated exon skipping restores ciliation in fibroblasts harboring the common Leber congenital amaurosis CEP290 mutation- Supplementary Information", Molecular Therapy-Nucleic Acids, Cell Press, US, US , (20120601), vol. 1, no. 6, doi:10.1038/mtna.2012.21, ISSN 2162-2531, pages E29 - E29-16, XP002716312

DOI:   http://dx.doi.org/10.1038/mtna.2012.21
    - Rob Wj Collin, Anneke I Den Hollander, Saskia D Van Der Velde-Visser, Jeannette Bennicelli, Jean Bennett, Frans Pm Cremers, "Antisense Oligonucleotide (AON)-based Therapy for Leber Congenital Amaurosis Caused by a Frequent Mutation in CEP290", Molecular Therapy — Nucleic Acids, (20120301), vol. 1, no. 3, doi:10.1038/mtna.2012.3, page e14, XP055088070

DOI:   http://dx.doi.org/10.1038/mtna.2012.3
    - Rakoczy P E, Lai M C, Watson M, Seydel U, Constable I., "Targeted delivery of an antisense oligonucleotide in the retina: uptake, distribution, stability, and effect", PROGRESS IN RETINAL AND EYE RESEARCH, OXFORD, GB, GB , (19960901), vol. 6, no. 3, doi:10.1089/oli.1.1996.6.207, ISSN 1350-9462, pages 207 - 213, XP002716313

DOI:   http://dx.doi.org/10.1089/oli.1.1996.6.207
    - Bochot A, Couvreur P, Fattal E., "Intravitreal administration of antisense oligonucleotides: Potential of liposomal delivery", PROGRESS IN RETINAL AND EYE RESEARCH, OXFORD, GB, GB , (20000301), vol. 19, no. 2, doi:10.1016/S1350-9462(99)00014-2, ISSN 1350-9462, pages 131 - 147, XP002716314

DOI:   http://dx.doi.org/10.1016/S1350-9462(99)00014-2
    - Feldherr Carl M, Et Al., "The permeability of the nuclear Envelope in Dividing and nondividing cell cultures", The Journal of Cell Biology, (19900701), vol. 111, XP055981225
    - GERARD XAVIER ET AL, "Intravitreal Injection of Splice-switching Oligonucleotides to Manipulate Splicing in Retinal Cells", Pharmacokinetics and Toxicity in Rats and Monkeys of coDbait: A Therapeutic Double-stranded DNA Oligonucleotide Conjugated to Cholesterol, MOLECULAR THERAPY-NUCLEIC ACIDS, VOL. 1, PAGE(S) ARTICLE NO.: E33, (20150901), vol. 4, ISSN 2162-2531(print), page Article No.: e250, XP002788928
    - GARANTO ALEJANDRO ET AL, "In vitro and in vivo rescue of aberrant splicing in CEP290-associated LCA by antisense oligonucleotide delivery", HUMAN MOLECULAR GENETICS, (20160615), vol. 25, no. 12, pages 2552 - 2563, XP002788931
    - Perrault Issabelle, Et Al., "Spectrum of NPHP6/CEP290 mutations in Leber congenital amaurosis and delineation of the associated phenotype", HUM MUTAT, (20070101), vol. 28, no. 4, XP055981226
    - NOBUYUKI ENDOH, MASATO UEHARA, HAJIME OGATA, ET AL., "SIMPLE MEASUREMENT METHOD OF NONLINEARITY PARAMETER B/A OF TISSUE BY PROPAGATION TIME DIFFERENCE.", Japanese journal of applied physics, Japan Society of Applied Physics, JP, JP , (19880301), vol. 27., no. SUPPL. 27-1., ISSN 0021-4922, pages 76 - 78., XP000036921
    - Andrieu-Soler, Et Al., "Single-stranded oligonucleotide-mediated in vivo gene repair in the rd1 retina", Mol Vis, (20070101), vol. 13, XP055981230
    - Rivka A Rachel;Tiansen Li;Anand Swaroop, "Photoreceptor sensory cilia and ciliopathies: focus on CEP290, RPGR and their interacting proteins", Cilia, BioMed Central Ltd, London, UK, London, UK , (20121203), vol. 1, no. 1, doi:10.1186/2046-2530-1-22, ISSN 2046-2530, page 22, XP021140457

DOI:   http://dx.doi.org/10.1186/2046-2530-1-22
    - Hocine, Et Al., "RNA processing and export", Cold Spring Harbor Perspectives In Biology, (20101201), vol. 2, no. 12, doi:10.1101/cshperspect.a000752, pages 1 - 21, XP055600420

DOI:   http://dx.doi.org/10.1101/cshperspect.a000752
    - Lambert Vincent, Et Al., "Laser-Induced choroidal neovascularization model in mice", Nat Protoc, (20130101), page 2197, XP055981232
    - Lenis Tamara L., Hu Jane, Ng Sze Yin, Jiang Zhichun, Sarfare Shanta, Lloyd Marcia B., Esposito Nicholas J., Samuel William, Jaworski Cynthia, Bok Dean, Finnemann Silvia C., Radeke Monte J., Redmond T. Michael, Travis Gabriel H., Radu Roxana A., "Expression of ABCA4 in the retinal pigment epithelium and its implications for Stargardt macular degeneration", Proceedings of the National Academy of Sciences, National Academy of Sciences, (20181120), vol. 115, no. 47, doi:10.1073/pnas.1802519115, ISSN 0027-8424, pages E11120 - E11127, XP055981234

DOI:   http://dx.doi.org/10.1073/pnas.1802519115
    - Han Zongchao, Makkia Rasha S, Cooper Mark, Naash Muna, "DNA nanoparticle-mediated ABCA4 delivery rescues Stargardt dystrophy in mice Nanoparticle applications in Physics View project Dose reconstruction for late effect studies in radiotherapy. View project", ArticleinThe Journal of clinical investigation, (20120101), vol. 122, no. 9, doi:10.1172/JCI64833·Source:, XP055981239

DOI:   http://dx.doi.org/10.1172/JCI64833·Source:
    - Wang, Et Al., "Proteomic evidence that ABCA4 is vital for traumatic proliferative vitreoretinopathy formation and development", Experimental Eye Research, (20190101), vol. 181, XP055981246
    - Fattal, E. Bochot, A., "Ocular delivery of nucleic acids: antisense oligonucleotides, aptamers and siRNA", Advanced Drug Delivery Reviews, Elsevier, Amsterdam , NL, Amsterdam , NL , (20061122), vol. 58, no. 11, doi:10.1016/j.addr.2006.07.020, ISSN 0169-409X, pages 1203 - 1223, XP005774959

DOI:   http://dx.doi.org/10.1016/j.addr.2006.07.020
    - Dos Santos Gomess, Et Al., "Intraocular Delivery of Oligonucleotides", CURR PHARM BIOTECHNOL, (20050101), vol. 6, XP055981255
    - Anand Manisha, Et Al., "Ciliary transition zone (TZ) proteins RPGR and CEP290: role in photoreceptor cilia and degenerative diseases", Expert Opin Ther Targets, (20120101), vol. 16, no. 6, XP055981260
    - Cideciyan Artur, Et Al., "Cone photoreceptors are the main targets for gene therapy of NPHP5 (IQCB1) or NPHP6 (CEP290) blindness: generation of an all-cone Nphp6 hypomorph mouse that mimics the human retinal ciliopathy", Human Molecular Genetics, (20110118), vol. 20, no. 7, XP055981269
    - Jazayeri, Et Al., "2013 ARVO Annual Meeting", (20130101), (20221115), XP055981272
    - Artur V. Cideciyan, Malgorzata Swider, Tomas S. Aleman, Yaroslav Tsybovsky, Sharon B. Schwartz, Elizabeth A.M. Windsor, Alejandro J. Roman, Alexander Sumaroka, Janet D. Steinberg, Samuel G. Jacobson, Edwin M. Stone, Krzysztof Palczewski, "ABCA4 disease progression and a proposed strategy for gene therapy", Human Molecular Genetics, Oxford University Press, GB, GB , (20090301), vol. 18, no. 5, doi:10.1093/hmg/ddn421, ISSN 0964-6906, pages 931 - 941, XP055378779

DOI:   http://dx.doi.org/10.1093/hmg/ddn421
    - Shah, Et Al., "Acanthocytosis", StatPearls, (20200101), StatPearls, (20221115), XP055981277
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.